Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520550 | 0.83 | CYP2A6 (0.68) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2089678 | 0.81 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2095364 | 0.80 | CA2 (0.51) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL6003431 | 0.80 | CYP2A6 (0.58) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL5541315 | 0.80 | CYP2A6 (0.58) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL4418009 | 0.79 | CYP2A6 (0.71) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL5543498 | 0.78 | CYP2A6 (0.65) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2094708 | 0.77 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL2949120 | 0.77 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 | |
| SCHEMBL156931 | 0.77 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2SMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP2A6 1153/4885KEAP1 2214/4885NFE2L2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.